The occurrence of HER2 alterations (including mutation, overexpression, and amplification) among NSCLC patients ranges from 2.4% to 38.0%, with a higher frequency observed in adenocarcinomas that exhibit well-differentiated histology. The gene discussed is ERBB2; the disease is adenocarcinoma.